Optimizing treatment in HIV/HCV coinfection

Area of Science:

• Hepatology
• Infectious Diseases
• Internal Medicine

Background:

• Hepatitis C virus (HCV) coinfection is common in individuals with human immunodeficiency virus (HIV).
• Sustained virological response (SVR) to anti-HCV treatment improves life expectancy in coinfected patients.
• Standard peginterferon plus ribavirin therapy yields low SVR rates, especially for HCV genotype 1.

Purpose of the Study:

• To evaluate the efficacy of novel anti-HCV drugs in patients coinfected with HIV.
• To assess the impact of Boceprevir and Telaprevir on SVR rates in treatment-naive HCV/HIV patients.
• To highlight considerations for managing HCV treatment in the context of HIV coinfection.

Main Methods:

• Pilot studies evaluated Boceprevir and Telaprevir in combination with peginterferon plus ribavirin.
• SVR rates were compared between novel drug regimens and standard therapy.
• Interim data on HCV RNA undetectability during treatment were analyzed.

Main Results:

• Boceprevir and Telaprevir significantly increased SVR rates compared to standard therapy (e.g., Telaprevir: 45% to 74%; Boceprevir: 26% to 61%).
• High rates of HCV RNA undetectability were observed during treatment.
• Drug-drug interactions between Boceprevir/Telaprevir and antiretrovirals limit concurrent therapy options.

Conclusions:

• Protease inhibitors like Boceprevir and Telaprevir offer improved SVR rates for HCV/HIV coinfection.
• Careful consideration of drug interactions and antiretroviral options is crucial.
• Future regimens with new anti-HCV drugs may offer better tolerability and efficacy.